Skip to content
Head to head

Arcutis Biotherapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ARQT · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

ARQT +0.7%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals trades cheapest on trailing earnings.
ARQTVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price26.36515.02
Change today-2.98%-1.08%
1-year return-3.5%+22.0%
Market cap$3.33B$130.58B
52-week range19.30 – 34.80412.27 – 568.67
Valuation
P/E (TTM)119.8233.14
P/E percentile, own 5-yr range99th99th
P/B13.676.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.1315.32
Net profit (TTM)$-16.44M$3.88B
Revenue (TTM)$508.68M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+45.1%+11.8%
Gross margin91.2%85.5%
Operating margin6.9%33.1%
Net margin5.9%30.7%
Free cash flow (TTM)$59.71M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership121.5%96.8%
Insider activity (12mo)20 buy / 26 sell28 buy / 22 sell
Short interest (% of float)14.4%1.9%
Analyst consensus100% buy (5)95% buy / 5% hold (21)
Analyst price target$42 (+59%)$624 (+21%)
StockVane view
StockVane Quant RatingD (33)C (68)
Company
Employees3546,400
Founded20161989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.